Roche halts lung drug combo test

Share this article:

Roche has canned its exploratory combination of onartuzumab and Tarceva among previously treated, advanced non-small cell lung cancer patients with MET-positive tumors.

The company said in a statement Monday that it halted Phase-III studies “due to a lack of clinically meaningful efficacy.”

The company also said the findings have prompted a review of its other onartuzumab clinical trials.

Monday's news follows a Reuters story that indicates that although Roche and Novartis have been buddying up of late that a merger is not in the works.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.